Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 373Neoplasms 323Neoplasm Metastasis 286Leukemia, Myeloid, Acute 277Breast Neoplasms 271Colorectal Neoplasms 238Melanoma 193Ovarian Neoplasms 191Recurrence 183Multiple Myeloma 178Prostatic Neoplasms 156Lung Neoplasms 156Pancreatic Neoplasms 152Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 146Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 114Carcinoma, Renal Cell 111Stomach Neoplasms 110Glioma 108Brain Neoplasms 105Advanced Solid Tumors 104Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 101Lymphoma 100Lymphoma, B-Cell 97Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 91

Interventions

dalpiciclib 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × HR+/HER2- Advanced Breast Cancer × 1 year × Clear all
NCT05586841 2026-05-29

Exploration of Dalpiciclib + Chidamide in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor: a Phase â… b Study

Beijing 302 Hospital

Phase 1 Completed
22 enrolled
Breast

HR+/HER2- Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡